India, July 27 -- Eikon Therapeutics Inc. (EIKN), a late-stage clinical biopharmaceutical company, on Monday reported dosing the first patient in the Phase 2/3 TeLuRide-008 trial evaluating EIK1001 in combination with pembrolizumab and chemotherapy for treating Stage 4 non-small cell lung cancer.
Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world, accounting for over 80%-85% of total lung cancer cases worldwide. The current standard of care for Stage 4 NSCLC combines immune checkpoint inhibitors (ICIs) like pembrolizumab plus histology-appropriate chemotherapy. The treatment confers significant clinical benefit over chemotherapy alone, yet many patients experience disease progression.
EIK1001 is an inve...